| Project/Area Number |
13557080
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 展開研究 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
CHIBA Shigeru (2003) The University of Tokyo, Faculty of Medicine, Associate Professor, 医学部附属病院, 助教授 (60212049)
平井 久丸 (2001-2002) 東京大学, 医学部附属病院, 助教授 (90181130)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
高橋 強志 東京大学, 医学部附属病院, 助手 (70332608)
小川 誠司 東京大学, 医学部附属病院, 客員助教授(常勤形態) (60292900)
千葉 滋 東京大学, 医学部附属病院, 講師 (60212049)
細谷 紀子 東京大学, 医学部附属病院, 助手 (00396748)
高橋 宗春 東京大学, 医学部・附属病院, 助手 (30313125)
|
|---|
| Project Period (FY) |
2001 – 2003
|
| Project Status |
Completed (Fiscal Year 2003)
|
| Budget Amount *help |
¥13,900,000 (Direct Cost: ¥13,900,000)
Fiscal Year 2003: ¥4,100,000 (Direct Cost: ¥4,100,000)
Fiscal Year 2002: ¥4,700,000 (Direct Cost: ¥4,700,000)
Fiscal Year 2001: ¥5,100,000 (Direct Cost: ¥5,100,000)
|
|---|
| Keywords | NKT cell / Vα24 / CD8+ / α-galactosy ceramide / CD1d / T lymphoblastic leukemia / リンパ腫 / IFN-γ / IL-4 / IL-10 / Th1 / Th2バランス / CDld / 慢性骨髄性白血病 / 免疫細胞療法 / 樹状細胞 / bcr / bal / 抹消血樹状細胞 / 探求由来樹状細胞 / 共刺激分子 / HLA分子 |
|---|
| Research Abstract |
We aimed at development of immunotherapy to hematological malignancies using NKT cells. Human NKT cells, ligands for which are CD1d/glycolipid complexes, utilize Va24 in TCR. As in mouse NKT cells, presence of CD4-CD8-and CD4+ subsets have been known in human NKT cells. In this project, we now newly identified the CD8+ subset. Moreover, we clarified the differences in the function among these subsets, particulaily the difference in the cytokine production profile.
We here found that human T cell neoplasms frequently express CD1d at a high level and that Va24NKT cells show anti-tumor activity against the CD1d+ T cell neoplastic cells. A glycolipid, a-galactosyl ceramide (a-GalCer), enhanced the anti-tumor activity of NKT cells in vitro. Therefore, direct administration of a-GalCer or administration of NKT cells that are expanded in vitro by a-GalCer could be a potential therapeutic option for T cell neoplastic diseases.
To further investigate such a possibility, we established an in vivo model for NKT cell-based anti-tumor therapy. A mouse precursor T cell tumor cell line, EL-4 expresses CD1d only at a weak level. We introduced CD1d cDNA into EL-4 and obtained cell lines overexpressing CD1d at various levels. In vitro, NKT-based cytotoxicity was stronger for EL-4 expressing CD1d at higher levels. Then, these cell lines were injected into syngenic B57BL/6 mice. We found that mice injected with EL-4 lines expressing higher levels of CD1d survived longer periods of time and that the survival time was extended by the administration of a-GalCer. These results indicate that endogenous NKT cells inhibit tumor growth through CD1d interaction.
We now creating a protocol on a clinical trial for T cell lymphoblastic leukemia using NKT cells.
|
